Barrett's esophagus is a well-recognized precursor of esophageal adenocarcinoma. Surveillance of Barrett's esophagus patients is recommended to detect high-grade dysplasia (HGD) or early cancer. Because of wide variation in the published cancer incidence in Barrett's esophagus, the authors undertook a systematic review and meta-analysis of cancer and HGD incidence in Barrett's esophagus. Ovid Medline (Ovid Technologies, Inc., New York, New York) and EMBASE (Elsevier, Amsterdam, the Netherlands) databases were searched for papers published between 1950 and 2006 that reported the cancer/HGD risk in Barrett's esophagus. Where possible, early incident cancers/HGD were excluded, as were patients with HGD at baseline. Forty-seven studies were included in the main analysis, and the pooled estimate for cancer incidence in Barrett's esophagus was 6.1/1,000 personyears, 5.3/1,000 person-years when early incident cancers were excluded, and 4.1/1,000 person-years when both early incident cancer and HGD at baseline were excluded. Corresponding figures for combined HGD/cancer incidence were 10.0 person-years, 9.3 person-years, and 9.1/1,000 person-years. Compared with women, men progressed to cancer at twice the rate. Cancer or HGD/cancer incidences were lower when only high-quality studies were analyzed (3.9/1,000 person-years and 7.7/1,000 person-years, respectively). The pooled estimates of cancer and HGD incidence were low, suggesting that the cost-effectiveness of surveillance is questionable unless it can be targeted to those with the highest cancer risk. adenocarcinoma; Barrett esophagus; esophageal neoplasms; incidence; meta-analysis; review Abbreviations: CI, confidence interval; LSBE, long-segment Barrett's esophagus; SIM, specialized intestinal metaplasia; SSBE, short-segment Barrett's esophagus.
In recent decades, the incidence of esophageal adenocarcinoma in the United States and Western Europe has risen at a more rapid rate than that of any other malignant neoplasm (1) (2) (3) (4) (5) . It is now the most common type of esophageal cancer in these countries (6) Barrett's esophagus is well recognized as a precursor of the majority of cases of esophageal adenocarcinoma (7) . It has been estimated that Barrett's esophagus carries a risk of cancer 30-125 times greater than that for an age-matched population (8) . Five-year survival following a diagnosis of esophageal adenocarcinoma is less than 15 percent (9, 10) . Hence, Barrett's esophagus surveillance has been recommended to detect dysplasia and early carcinoma (11, 12) . Several studies have now shown that patients diagnosed with esophageal adenocarcinoma within a surveillance program have earlier-stage disease and longer survival times than patients diagnosed outside such programs (13) (14) (15) . However, the cost-effectiveness of Barrett's esophagus surveillance is dependent on cancer risk (16) . Wide variation in this risk has been observed, ranging from 0 percent to 3 percent per annum (17) .
To date, there have been three known published systematic reviews of the incidence of cancer in Barrett's esophagus (17) (18) (19) . However, in all three, the literature search was limited to studies published in the English language, and two searched only the Medline database (17, 18) . In addition, one of these included only those patients who had undergone medical or surgical treatment (18) , and two of the studies (17, 18) did not include high-grade dysplasia as an outcome. Furthermore, patients with high-grade dysplasia at baseline, who have a high risk of progression to malignancy (20) (21) (22) (23) (24) (25) , were not excluded from any of the studies, and quality criteria for the selection of studies were not applied.
We undertook this systematic review to include all papers irrespective of language of publication and to exclude prevalent high-grade dysplasia. We included high-grade dysplasia as an outcome, applied quality criteria to the studies, and undertook analyses based on them. We also investigated the variation in cancer/high-grade dysplasia incidence in Barrett's esophagus by geographic location and other factors such as length of Barrett's segment and sex.
MATERIALS AND METHODS
Both Ovid Medline (Ovid Technologies, Inc., New York, New York) and EMBASE (Elsevier, Amsterdam, the Netherlands) databases were searched for all papers published in any language between 1950 and 2006 that reported the cancer or high-grade dysplasia risk in Barrett's esophagus. The two main search strategies combined the results of keyword searches for Barrett's esophagus and for cancer. The following keywords for Barrett's esophagus were used: Barrett's esophagus, Barrett's metaplasia, Barrett's mucosa, Barrett's epithelium, columnar lined esophagus, or specialized intestinal metaplasia (SIM). The keywords used for cancer and dysplasia were the following: adenocarcinoma, esophageal cancer, esophageal neoplasm, esophageal neoplasia, adenosquamous tumor, or dysplasia. These terms were used as keyword and mapped terms, and both American and English spellings were allowed.
Duplicate publications were removed. Each title and abstract was independently reviewed by two researchers to determine whether the paper was relevant to the review topic. The full text was reviewed if the abstract indicated that the paper reported cancer or high-grade dysplasia risk in Barrett's esophagus patients. The bibliographies of these articles were also scanned to identify additional articles. Papers were incorporated in the review if they included a follow-up period and reported the incidence of esophageal cancer or high-grade dysplasia in Barrett's esophagus irrespective of the definition of Barrett's esophagus used-for example, endoscopically or histologically confirmed, shortsegment Barrett's esophagus (SSBE) or long-segment Barrett's esophagus (LSBE), SIM present or not.
Studies were excluded if they were available as abstracts only. they reported esophageal cancer incidence in familial Barrett's esophagus patients.
they reported esophageal cancer incidence in Barrett's esophagus in intellectually disabled patients. they reported esophageal cancer incidence in Barrett's esophagus in children. they reported only those patients who underwent antireflux surgery. all patients had dysplasia at baseline.
If serial publications reported cancer risk in the same cohort, only the most recent report was included. However, information was obtained from earlier reports for subgroup analysis if the most recent studies did not include the required information.
Data extraction
The first author (F. Y.) and one of the other authors (L. M., M. C., or K. G.) extracted data independently from each study by using standardized proformas (this data extraction form is posted on the Journal's website (http://aje.oupjournals. org/)), and any disagreement was resolved by discussion. The following data were extracted, where available: study location; year and language of publication; definition of Barrett's esophagus used; number of patients in the study; number of patients for whom follow-up information was available; mean follow-up period; person-years of followup; mean age of patients; and proportion of patients at baseline who were male, were female, had LSBE (3 cm) or SSBE (<3 cm), had SIM, or had low-grade dysplasia or high-grade dysplasia. The following data were also collected, where available, to evaluate the outcomes of interest: total number of cancers and high-grade dysplasias, number of incident cancers and high-grade dysplasias (if patients developed a cancer after high-grade dysplasia, only the cancer was counted), period used to exclude early incident cancer and high-grade dysplasias, and number of early incident cancers and high-grade dysplasias. When the authors of the reports excluded early incident cancers, it generally was for those occurring within the first 6 or 12 months after Barrett's esophagus diagnosis. Both thresholds were accepted unless cancers occurring between 6 and 12 months could be excluded on further examination of the published data. In general, the authors of the reports did not exclude high-grade dysplasias occurring within the first year, but some reports provided information to enable these cases to be excluded.
Quality criteria
Three factors were considered indicators of good study quality: 1) large study size (i.e., 500 person-years), 2) application of a robust definition of Barrett's esophagusclinically visible segment and histologically confirmed SIM, and 3) low likelihood of selection bias. Selection bias was assessed by calculating the proportion of all Barrett's esophagus patients in the population under study for whom followup data were provided (or for whom follow-up was not appropriate, e.g., prevalent esophageal cancer). Studies that did not provide information to enable this proportion to be calculated or in which the proportion was less than 70 percent were considered to be affected by selection bias. Exclusion of studies on the basis of each of these quality criteria would have resulted in the omission of 23, 32, and 18 studies, respectively. If all quality criteria had been applied, all but eight studies would have been excluded. Therefore, instead of excluding these studies, we conducted subgroup analyses according to the criteria.
Calculating esophageal cancer and high-grade dysplasia incidence in each study All studies excluded prevalent cancers at baseline. For each study, the incidence of cancer in Barrett's esophagus was calculated by dividing the number of incident cancers by the total number of person-years of observation. When the information could be extracted, participants with early incident cancer (cancer occurring in the first year) and highgrade dysplasia at baseline were excluded. If the total number of person-years of follow-up was not reported, it was calculated by multiplying the number of patients under follow-up by mean duration of follow-up. For studies that reported median age only, this information was used to approximate mean age. The combined incidence of cancer and high-grade dysplasia was calculated in a similar way.
Pooled analyses
Exact methods, based on the Poisson distribution, were used to calculate 95 percent confidence intervals for the rate of cancer/high-grade dysplasia for presentation in forest plots. Meta-analysis models were applied by using the log incidence rates of cancer/high-grade dysplasia and corresponding standard errors. When the counts of cancer/highgrade dysplasia were zero, a correction of 0.5 was added to the number of cases and person-years of follow-up, prior to calculation, as previously described (26) . Heterogeneity between studies was investigated by using the v 2 test and was measured by using the I 2 statistic (27) . The I 2 statistic measures the proportion of variation in the study estimates due to heterogeneity. A random-effects model (28) was used to calculate a pooled estimate of the incidence rate from the combined studies.
An alternative analysis that did not involve any corrections for zero counts of cancer/high-grade dysplasia was conducted by using a two-stage method (29) to summarize the incidence rate at the study level and to produce an average incidence rate (and 95 percent confidence interval) based upon the mean and standard deviation of the study incidence rates. This analysis produced similar results and is therefore not shown in this paper.
Publication bias was investigated by examining funnel plots and by using Begg's and Egger's test that used a liner regression approach to measure funnel plot asymmetry on the natural logarithm scale of odds ratio (30, 31) . All statistical analyses were performed by using Stata version 9.2 software (Stata Corporation, College Station, Texas).
All studies that met inclusion criteria were included in the principal analyses. Repeat analyses included only those studies in which early incident cancers or patients with high-grade dysplasia at baseline could be excluded. Subgroup analyses, which were identified a priori, were performed on the basis of the quality criteria and according to sex, length of segment, presence of SIM, and definition of Barrett's esophagus used.
RESULTS
The Ovid Medline and EMBASE searches yielded 3,896 and 5,610 entries, respectively (figure 1). Following removal of duplicates, 7,780 abstracts were assessed and 209 articles appeared to be appropriate for inclusion in the review. The full-text papers were evaluated, and 80 papers met the criteria. Another nine papers were added following review of the bibliographies of these papers. Data were extracted from these 89 studies. Nineteen studies (32-50) were excluded because the incidence of cancer or high-grade dysplasia in Barrett's esophagus could not be calculated, and 23 repeated studies were also excluded. Forty-seven studies were therefore included in the analysis of cancer incidence in Barrett's esophagus patients (figure 1).
Study characteristics
Of the 47 studies included in the review, 17 were from the United Kingdom, 13 from other European countries, 13 from the United States, and four from other countries. The overall mean age was 59.6 years in the 35 studies providing this information. Twenty-seven studies reported the sex of the Barrett's esophagus patients, with a mean overall male percentage of 68 percent. Twenty-five studies reported the length of Barrett's esophagus, and the mean percentage of LSBE was 92 and the mean percentage of SSBE was 7.7 in these studies. Twenty-five studies reported the percentage of Barrett's esophagus patients with SIM, and the overall mean percentage who were SIM positive was 90 percent. Seventeen studies reported the proportion of Barrett's esophagus patients undergoing routine surveillance, with an overall mean of 77 percent. Twenty-one studies reported the percentage of Barrett's esophagus with low-grade dysplasia at baseline: the overall percentage of low-grade dysplasia in these studies was 15.7 percent (table 1) .
Overall incidence of cancer in Barrett's esophagus. All 47 studies provided data that could be used for the analysis of cancer incidence in Barrett's esophagus patients. The studies included 11,279 patients followed up for 47,496 person-years, in whom 209 cancers occurred. The average cancer incidence in Barrett's esophagus was 6.1 per 1,000 person-years (95 percent confidence interval (CI): 4.7, 7.9) (figure 2). However, there was evidence of considerable heterogeneity in the incidence rates (v 2 ¼ 135.4, df ¼ 46, p < 0.001; I 2 ¼ 66 percent). In 29 studies in which the early incident cancers within 1 year could be excluded, the average incidence rate of cancer in Barrett's esophagus was 5.3 per 1,000 person-years (95 percent CI: 3.8, 7.4), but again there was marked heterogeneity (v 2 ¼ 77.4, df ¼ 28, p < 001; I 2 ¼ 64 percent). In 12 studies, both the early incident cancers and patients with high-grade dysplasia at baseline could be removed, the average incidence rate was 4.1 per 1,000 person-years (95 percent CI: 3.1, 5.5), and there was
The mean incidence rate in the United Kingdom studies was 7.0 per 1,000 person-years (95 percent CI: 4.2, 11.5). In US studies, it was 6.4 per 1,000 person-years (95 percent CI: 4.1, 9.8), and in other European countries studies it was 5.6 per 1,000 person-years (95 percent CI: 3.7, 8.5).
Incidence of both cancer and high-grade dysplasia.
Twenty-five studies ( Table 2 shows the results of subgroup analyses. Six studies (61, 66, 84, 89, 98, 108) reported the incidence of cancer in men, giving a pooled estimate of 10.2 per 1,000 personyears. The pooled incidence in females (five studies (61, 84, 89, 98, 108) ) was 4.5 per 1,000 person-years. Twenty-six studies (52, 54, 60, 66, 67, 73, 75, 76, 81, 83, 85, 88, 89, 92, 93, 96, 97, 101, 102, 105, 107, 111, (116) (117) (118) 120) reported the incidence of cancer in LSBE, with a pooled estimate of 6.7 per 1,000 person-years, while the pooled incidence in SSBE (six studies (54, 63, 64, 74, 86, 102) 
Included in analysis 47
Repeated studies 23
Incidence could not be calculated 19
Identified from references 9 Incidence rate per 1,000 person-years FIGURE 2 . Forest plot of random-effects meta-analysis of the incidence of cancer in Barrett's esophagus. CI, confidence interval.
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Application of quality criteria Table 2 also shows the pooled cancer incidence after applying the quality criteria: study size greater than 500 person-years, low likelihood of selection bias, and a robust definition of Barrett's esophagus applied. When only those studies including 500 person-years or more were considered, the pooled incidence was 4.4 per 1,000 person-years and the combined high-grade dysplasia and cancer incidence was 7.4 (95 percent CI: 5.3, 10.3) per 1,000 personyears. The same estimate of cancer risk (4.4 per 1,000 person-years) was also obtained when only those studies applying a robust definition of Barrett's esophagus were included, while the combined high-grade dysplasia and cancer incidence was 9.5 (95 percent CI: 6.0, 15.0) per 1,000 person-years. A pooled cancer estimate of 4.9 per 1,000 person-years (incidence of 8.5, 95 percent CI: 5.6, 12.7 per 1,000 person-years for cancer and high-grade dysplasia) was produced when only those studies with less likelihood of selection bias were included. Only eight studies met all three quality criteria, and the pooled estimate of cancer incidence was 3.9 per 1,000 person-years. Seven studies meeting all three quality criteria gave a pooled estimate for both cancer and high-grade dysplasia of 7.7 (95 percent CI: 4.7, 12.7) per 1,000 person-years. The heterogeneity in the subgroup analysis was substantially lower than in the overall analysis.
Publication bias
A funnel plot is shown in figure 4 . Although tests of funnel plot asymmetry were not statistically significant (Begg's test, p ¼ 0.24; Egger's test, p ¼ 0.92), the funnel plot displayed some evidence of larger, more extreme estimates in the smaller studies, which would be consistent with publication bias. This finding is consistent with the smaller incidence rate noted in the larger studies described in table 2. Publication bias was also assessed by Begg's and Egger's test among studies from different geographic areas, and there was no evidence of publication bias within the US, United Kingdom, or European studies. 
DISCUSSION
This systematic review showed that the overall estimate of cancer incidence in Barrett's esophagus was 6.1 cases per 1,000 person-years (0.61 percent per year or 1 in 164 person-years). This incidence is slightly higher than that reported by Shaheen et al. (17) , who used a different approach to estimate cancer incidence. It is similar to that observed in the medically treated Barrett's esophagus group in a recent review (18) that compared cancer incidence in medically and surgically treated patients, and it is slightly lower than that reported in the most recently published review (19) . However, only one of these reviews excluded early incident cancers and none excluded cancers occurring in patients with high-grade dysplasia at baseline, which will inflate the risk of cancer for patients with uncomplicated Barrett's esophagus. When we limited our analysis to studies in which these two groups were excluded, the cancer incidence was 4.1 per 1,000 person-years (0.41 percent per year or 1 in 244 person-years), which is likely to be a more robust estimate of the cancer incidence in Barrett's esophagus patients.
The occurrence of high-grade dysplasia is an important outcome in Barrett's surveillance programs because its detection provides an opportunity to prevent progression to invasive cancer through esophagectomy (121) or other interventions, such as photodynamic therapy (122) and endoscopic mucosal resection (123) . We therefore calculated a combined incidence of cancer and high-grade dysplasia. The pooled estimate of cancer and high-grade dysplasia incidence was 10.0 per 1,000 person-years of follow-up, declining to 9.1 per 1,000 (1 in 110 person-years or 0.91 * Analyses were not restricted to studies in which early incident cancers or patients with high-grade dysplasia at baseline could be excluded. y CI, confidence interval; LSBE, long-segment Barrett's esophagus; SSBE, short-segment Barrett's esophagus; SIM, specialized intestinal metaplasia.
z Selection bias was considered likely if <70% of Barrett's esophagus patients in the center/population were followed up in the study. § Endoscopically visible segment and histologically confirmed SIM. { Person-years >500, no selection bias, and well-defined Barrett's esophagus. Incidence rate per 1,000 person-years percent per year) when early incident cancers (or high-grade dysplasia) or cancers occurring in patients with high-grade dysplasia at baseline were excluded. The later incidence is similar to that reported by Thomas et al. (19) even though cancers occurring in patients with high-grade dysplasia at baseline were not excluded. The quality of the published studies included in this review was highly variable. We considered a number of parameters as quality criteria and decided to apply study size, likelihood of selection bias, and application of a robust definition of Barrett's esophagus. However, because many of the studies were small, did not apply robust criteria for Barrett's esophagus diagnosis, had low follow-up rates, or did not provide information to enable the reader to assess the proportion of patients who were followed up, we undertook subgroup analyses on the basis of these criteria rather than excluding lower-quality studies. Cancer incidence was much lower in large rather than small studies: 4.4 per 1,000 person-years in studies with 500 person-years or more compared with 11.6 per 1,000 in smaller studies. This finding is similar to that of Thomas et al. (19) , who reported a low incidence of 5 per 1,000 person-years when they excluded studies with less than 200 person-years.
Three explanations for this finding are possible. First, smaller studies may have included a biased selection of Barrett's esophagus patients with a high cancer risk (e.g., patients referred to specialist treatment centers). Second, large studies may not have been able to identify all incident cases of cancer. Third, there may have been bias against the publication of small studies showing low cancer incidence, but there was little evidence of publication bias in this study. Similarly, studies achieving high follow-up rates or using a robust definition of Barrett's esophagus reported lower cancer incidence than other studies did. Only eight studies met all three quality criteria (seven of which included highgrade dysplasia as an outcome); cancer incidence in these studies was 3.9 per 1,000 person-years, while cancer and high-grade dysplasia incidence was 7.7 per 1,000 personyears. Although these data are from few studies, the studies were large (including almost 14,000 person-years in total and 51 incident cancers) and well performed. Therefore, they are most likely to provide the best estimate of the true incidence of cancer and high-grade dysplasia in uncomplicated Barrett's esophagus.
Information was not available to calculate the incidence in SIM-negative Barrett's esophagus, but, surprisingly, the pooled incidence of cancer in SIM-positive cases (4.7 per 1,000 person-years) was lower than that in all studies (6.1 per 1,000 person-years), which will have included patients without SIM. This may have occurred because the studies providing information regarding SIM status were, in general, large (14 of 20 studies included 500 or more personyears) and provided sufficient information to exclude early incident cancers (18 of 20 studies), thereby resulting in a lower incidence compared with all studies combined.
Few studies provided data to calculate cancer incidence for men and women. However, in the studies that did provide these data, cancer incidence in men was more than twice that in women, which is in keeping with the male predominance among patients with esophageal adenocarcinoma (1, 124) and with studies that show male sex to be a risk factor for progression to cancer (33, 125) . We did not find any geographic variation in cancer incidence in Barrett's esophagus. Geographic differences in the population incidence of esophageal adenocarcinoma are well described (2, 5), including a higher incidence in the United Kingdom compared with the United States. Jankowski et al. (126) have suggested that this finding was due to a higher rate of progression from Barrett's esophagus to esophageal adenocarcinoma in the United Kingdom, but our findings do not support this hypothesis. Thomas et al. (19) also reported no geographic variation in Barrett's esophagus cancer risk.
Previous studies (54, 83, 127, 128) indicate that patients with LSBE are at a higher risk of developing cancer than patients with SSBE. In contrast, this review showed no difference in the overall cancer incidence between patients with LSBE or SSBE. However, only six studies provided data to calculate the incidence of cancer in SSBE, and these studies included 1,400 person-years and only seven incident cancers. Our study cannot therefore conclude, with any certainty, that there is no difference in cancer incidence between SSBE and LSBE. The study by Thomas et al. (19) showed a trend toward lower incidence in patients with SSBE, but this analysis was also based on data from a small number of studies.
The funnel plot shows some evidence of publication bias, but the Egger's and Begger's tests were not statistically significant. This finding was in keeping with those of Thomas et al. (19) . Conversely, Shaheen et al. (17) concluded that publication bias was present in their review. Inclusion of foreign language papers, more recent publications, and several earlier references that Shaheen et al. did identify may explain the difference in the findings of our review and that of Shaheen et al. There was substantial heterogeneity between studies included in our review, with the risk of esophageal cancer in individual studies varying between 0 and 35.5 cases per 1,000 person-years and an I 2 value of 66 for the combined estimate of cancer incidence. Many factors may have contributed to this heterogeneity, including temporal difference in the studies, study size, proportion of Barrett's esophagus patients followed up, geographic location of studies, definitions of Barrett's esophagus used, and age and distribution of patients. Because of an evident heterogeneity, we applied random-effects models and undertook subgroup analyses where possible, based on the quality criteria. Heterogeneity was substantially reduced in the subgroup analyses, and the results of these analyses may therefore be more reliable.
When data from only the high-quality studies were analyzed, a low incidence of esophageal adenocarcinoma in Barrett's esophagus was found, at 3.9 per 1,000 person-years; the combined incidence of esophageal adenocarcinoma and high-grade dysplasia was somewhat higher at 7.7 per 1,000 person-years. Published data indicate that 19-59 percent of cases of high-grade dysplasia progress to cancer (129) . If 40 percent of the incident high-grade dysplasia cases in the studies do not progress to cancer, then the overall risk of cancer in Barrett's esophagus can be estimated to be 6.3 per 1,000 person-years (0.63 percent per year).
To date, we know of no randomized controlled trials of Barrett's esophagus surveillance that have been published, Esophageal Cancer and Dysplasia in Barrett's Esophagus 245 so several authors have used mathematical models to explore the cost-effectiveness of surveillance (16, 130, 131) . Despite different modeling approaches and the application of different costs, these studies confirm that the costeffectiveness of surveillance is crucially dependent on the incidence of cancer in Barrett's esophagus. On the basis of costs in the United States, Provenzale et al. (16) concluded that, for a cancer risk of 5 per 1,000 person-years, surveillance every 4 years was indicated and, if the risk was 0.4 percent year, surveillance every 5 years was the only strategy that increases quality of life. Modeling surveillance from a United Kingdom perspective, Garside et al. (131) concluded that, at a cancer risk equivalent to 0.5 percent per year, no surveillance costs less and results in a better quality of life than surveillance, irrespective of the surveillance interval used. The estimates of cancer incidence obtained from this systematic review are close to those used in these models and clearly indicate that the cost-effectiveness of Barrett's surveillance is questionable unless it can be targeted to those Barrett's esophagus patients who are at the highest risk of cancer.
In conclusion, this study showed substantial heterogeneity between the published reports that have examined the risk of cancer or high-grade dysplasia in Barrett's esophagus. Men progressed to cancer at twice the rate of women, but no clear difference was found in the rate of progression for patients with SSBE or LSBE, and no geographic variation in progression to cancer was evident. When highquality studies were examined, the rates of progression to cancer or cancer and high-grade dysplasia combined were low (0.39 percent per year and 0.77 percent per year, respectively), which calls into question the cost-effectiveness of endoscopic surveillance of Barrett's esophagus.
